PhotonMD® Announces Commercial Sales of REVIAN® RED System
Written November 6, 2019
PhotonMD, Inc., an innovative photomedicine device company, announced its REVIAN RED system, an FDA cleared, over-the-counter (OTC) light therapy system for the treatment of androgenetic alopecia in both men and women is now shipping to customers.
“We have been greatly encouraged by the enthusiasm surrounding the launch of REVIAN RED and are excited to offer our treatment solution to help the 80 million Americans living with androgenetic alopecia, or pattern hair loss. It is important to give patients a convenient, effective, and safe solution without negative side effects for this chronic and progressive condition,” states President and Chief Executive Officer, Dr. Nicholas Medendorp, Jr.
The REVIAN RED system uses a wireless smart Cap and companion mobile app controller to stimulate natural hair growth in just 10-minutes a day. The revolutionary medical device combines a proprietary application of specific wavelengths of light with a first-of-its-kind smartphone mobile app (iOS or Android) allowing patients to control, schedule and monitor their daily 10-minute treatments for an effortless regrowth experience.
“The REVIAN RED system is offered at $749 and is an exceptional choice for men and women who are seeking a chemical-free hair growth solution in the privacy of their own home with zero mess or side effects,” said Medendorp.
PhotonMD is a modern medical device company focused on identifying and developing natural, chemical free, non-UV containing light technologies that will enable the treatment of chronic diseases. The products treat various health conditions using Modulated Light Therapy™ (MLT) technology that play an important role in unlocking key elements in human physiology. The company is dedicated to pushing the boundaries of scientific research around light-based therapy and designing innovative and safe solutions that dramatically improve the lives of patients. For more information about PhotonMD, please visit PhotonMD.com.
Except for historical information, all the statements, expectations, and assumptions contained in this press release are forward-looking statements. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: reliance on key personnel; the early stage of our business; risks associated with the medical device development processes; competition; and other risks described in other Company press releases and presentations. PhotonMD assumes no obligation and do not intend to update these forward-looking statements, except as required by law.